A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and tolerability, pharmacokinetics,
pharmacodynamics and anti-tumor activity of MK2206 when administered with Every Other Day
(QOD) and Once Weekly (QW) dosing schedules.